Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.…
Apimeds Pharmaceuticals US Reports Third Quarter 2026 Results, Delivers First Operating Revenue from Technology Services
Apimeds Pharmaceuticals US (NYSEAMERICAN: APUS) is listed on NYSE American, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.
The shares were at 1.600 USD on 20 November 2026, down 99.5% over 52 weeks. Its 52-week range is 1.510 USD to 332.00 USD: the price is 99.5% below the high and 6.0% above the low.
Its market capitalisation is 2.96M USD.
Apimeds Pharmaceuticals US reports return on equity of -3.9% and an operating margin of 0.0%.
Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.